DDrare: Database of Drug Development for Rare Diseases

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5-Methyl-1-Phenyl-2-1-(H)-Pyridone; AZITHROMYCIN; AZITHROMYCIN DIHYDRATE; AZITHROMYCINE; AZITHROMYCINE 250 mg; AZM; Adipate; Aerolised Liposomal Ciclosporin A; Aerolised Liposomal Ciclosporin A 10mg; Aerolised Liposomal Ciclosporin A 5mg; Azithromycin; Azithromycin (Zitromax°); Azithromycin + N-acetylcystein + inhaled corticosteroid; Azithromycine; Aztreonam; Aztreonam Lysine for Inhalation (AZLI); Basiliximab; Bortezomib; Budesonide; Budesonide/formoterol; CICLOSPORIN A; COLECALCIFEROL; Certican; Certican 0,5; Certican 0,5 mg Tabletten; Certican 0,75mg; Certican 0,75mg Tabletten; Chloride; Ciclosporin; Ciclosporin (Ciclosporinium); Ciclosporina; Ciclosporina / Ciclosporin; Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A; Ciclosporina/ Ciclosporin; Ciclosporine; Ciclosporine A; Ciclosporine, Ciclosporina; Ciclosporine, ciclosporina; Clarithromycin; Cloruro de Sodio; Cloruro de sodio; Colecalciferol; CsA; Cyclosporine; Cyclosporine A dry powder inhalation (Drug); Cyclosporine Inhalation Solution; Cyclosporine Inhalation Solution (CIS); D-Cure; D-cure; ERL080; Enteric coated mycophenolate sodium; Erythromycin; Esbriet; Etanercept; Everolimus; FAM Therapy; Fluticasone; Fluticasone propionate; Formoterol; Formoterol/Budesonide; Glucocorticoid; Helium; Helium-3; Hp 129Xenon; Hyperpolarized Helium-3 MRI; INTERFERON GAMMA-1B; Imukin; Inhalation; Interferon Gamma; Interferon gamma 1b; Interferon gamma-1b; Itacitinib; Itacitinib Adipate; L-CsA; Lactose; Liposomal Cyclosporine A; Liposomal Cyclosporine A 10 mg; Liposomal Cyclosporine A 5 mg; Liposomal aerosol cyclosporine; Lysine; MONTELUKAST SODIUM; MPH966; MSCs; Mesenchymal stem cell 0.5; Mesenchymal stem cell 1.0; Montelukast; Montelukast Teva; Montelukast sodium; Montelukast teva; Mycophenolate; Myfortic; Nintedanib; OFEV; OTHER SOURCES; Other: EIT; Other: Inhaled Hyperpolarized Xenon-129; Other: Salbutamol nebulisation and with CPAP; Other: standard immune suppression, oral; PIRFENIDONE; Pirfenidone; Pirfenidone 267 MG [Esbriet]; Prednisone; Procedure: Pulmonary function testing; Procedure: Status Post Lung Transplant; RAD001; Ruxolitinib; Salbutamol; Seretide; Singulair; Singulair (Montelukast Sodium); Sodium Chloride; Sodium Chloride Solution; Sodium Chloride Solvent; Sodium Chloride solvent; Sodium chloride; Solucion de Cloruro de Sodio; Solucion de cloruro de sodio Sodium Chloride Solution; Solvente Cloruro de Sodio Sodium Chloride Solvent; Solvente de Cloruro de Sodio; Symbicort; Tacrolimus; Vitamin D; Xenon; Zithromax; Zitromax

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03315741 (ClinicalTrials.gov)	March 1, 2018	5/10/2017	The Safety and Tolerability of Pirfenidone for BOS After HCT	The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation	Bronchiolitis Obliterans;Graft Vs Host Disease	Drug: Pirfenidone 267 MG [Esbriet]	Stanford University	Genentech, Inc.	Recruiting	18 Years	N/A	All	30	Phase 1	United States
2	EUCTR2014-002022-12-SE (EUCTR)	06/08/2015	15/10/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone	Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
3	EUCTR2014-002022-12-NL (EUCTR)	13/05/2015	03/11/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	Belgium;Denmark;Germany;Netherlands;United Kingdom;Sweden
4	NCT02262299 (ClinicalTrials.gov)	May 2015	21/9/2014	European Trial of Pirfenidone in BOS, A European Multi-center Study	A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients	Disorder Related to Lung Transplantation;CLAD, Bronchiolitis Obliterans	Drug: Pirfenidone;Drug: Placebo	Rigshospitalet, Denmark	NULL	Completed	18 Years	N/A	All	90	Phase 2;Phase 3	Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom
5	EUCTR2014-002022-12-BE (EUCTR)	10/03/2015	15/10/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000015490;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone	Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2014-002022-12-GB (EUCTR)	06/01/2015	15/10/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90	Phase 2	Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
7	EUCTR2014-002022-12-DE (EUCTR)	30/12/2014	21/10/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 2	Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden
8	EUCTR2014-002022-12-DK (EUCTR)	15/12/2014	04/11/2014	European Trial of Pirfenidone in BOS (EPOS).	A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial	Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone	Clinical Trials Unit, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90	Phase 2	Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03315741
(ClinicalTrials.gov)

March 1, 2018

5/10/2017

The Safety and Tolerability of Pirfenidone for BOS After HCT

The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation

Bronchiolitis Obliterans;Graft Vs Host Disease

Drug: Pirfenidone 267 MG [Esbriet]

Stanford University

Genentech, Inc.

Recruiting

18 Years

N/A

All

Phase 1

United States

EUCTR2014-002022-12-SE
(EUCTR)

06/08/2015

15/10/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden

EUCTR2014-002022-12-NL
(EUCTR)

13/05/2015

03/11/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Germany;Netherlands;United Kingdom;Sweden

NCT02262299
(ClinicalTrials.gov)

May 2015

21/9/2014

European Trial of Pirfenidone in BOS, A European Multi-center Study

A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients

Disorder Related to Lung Transplantation;CLAD, Bronchiolitis Obliterans

Drug: Pirfenidone;Drug: Placebo

Rigshospitalet, Denmark

NULL

Completed

18 Years

N/A

All

Phase 2;Phase 3

Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom

EUCTR2014-002022-12-BE
(EUCTR)

10/03/2015

15/10/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000015490;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-002022-12-GB
(EUCTR)

06/01/2015

15/10/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden

EUCTR2014-002022-12-DE
(EUCTR)

30/12/2014

21/10/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s).
MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden

EUCTR2014-002022-12-DK
(EUCTR)

15/12/2014

04/11/2014

European Trial of Pirfenidone in BOS (EPOS).

A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial

Trade Name: Esbriet
Product Name: Pirfenidone
INN or Proposed INN: PIRFENIDONE
Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone

Clinical Trials Unit, Rigshospitalet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden